Selexis CHO Cells in Suspension-1

Archives

Selexis has been setting the pace of innovation in protein expression and establishing new benchmarks in bioproduction for  two decades.

JUNE 29, 2021
3 min read

Selexis and KBI Biopharma Enter into Agreements with Immatics for Integrated Approach to Advance Immatics TCR Bispecific Program Towards IND

Geneva, Switzerland, and Durham, NC – June 29, 2021Selexis SA and KBI Biopharma (KBI), both JSR Life Sciences...

Read More
JUNE 1, 2021
2 min read

Selexis Appoints Roland Hoffmann-Hecht, PhD, as Chief Business Officer

Business Development Executive in Biologics Drug Development and Manufacturing Brings More than 25 Years of...

Read More
MAY 27, 2021
3 min read

Great Place to Work® Designates Selexis as One of the Best Workplaces™ Switzerland for Fourth Straight Year

Geneva, Switzerland, May 27, 2021  Selexis SA, a JSR Life Sciences company, announced today that Great Place to Work® ...

Read More
MARCH 23, 2021
4 min read

Selexis and Tallac Therapeutics Collaborate to Advance Tallac’s Pipeline of Novel Immunotherapies in Oncology

Tallac Will Draw on Selexis’ Best-in-Class Cell Line Development Technologies Under New Commercial License and Service...

Read More
MARCH 18, 2021
3 min read

SpyBiotech Licenses Selexis Best-in-Class Cell Line Development Technologies to Advance Human Cytomegalovirus VLP Vaccine Program

Geneva, Switzerland, March 18, 2021  Selexis SA, a JSR Life Sciences company, and SpyBiotech, a biotechnology company...

Read More
MARCH 16, 2021
2 min read

Selexis Enters Service Agreement with Pandion Therapeutics to Advance Pandion Antibody

Pandion will leverage Selexis’ proprietary technology platform to advance an antibody targeting autoimmune and...

Read More
OCTOBER 20, 2020
6 min read

JSR Life Sciences Expands its European Gene-to-GMP Biologics Manufacturing Facilities for Selexis and KBI Biopharma in Geneva, Switzerland

SUNNYVALE, California, October 20, 2020JSR Life Sciences, LLC today announced that it is increasing its European...

Read More
OCTOBER 16, 2020
4 min read

Selexis Names Biopharmaceutical Executive Dirk Lange as New Chief Executive Officer

Geneva, Switzerland, October 16, 2020Selexis SA, a JSR Life Sciences Company, today announced the appointment of...

Read More
SEPTEMBER 2, 2020
4 min read

Igyxos and Selexis Enter Service Agreement to Advance Igyxos’ First-In-Class Monoclonal Antibody for the Treatment of Human Infertility

Geneva, Switzerland, and Nouzilly, France, September 2, 2020  Selexis SA and Igyxos announced today that they have...

Read More